Frequency Therapeutics Stock Alpha and Beta Analysis
| KRRO Stock | 52.31 1.69 3.34% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Frequency Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Frequency Therapeutics over a specified time horizon. Remember, high Frequency Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Frequency Therapeutics' market risk premium analysis include:
Beta 3.87 | Alpha 0.31 | Risk 12.72 | Sharpe Ratio 0.0493 | Expected Return 0.63 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Frequency |
Frequency Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Frequency Therapeutics market risk premium is the additional return an investor will receive from holding Frequency Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Frequency Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Frequency Therapeutics' performance over market.| α | 0.31 | β | 3.87 |
Frequency Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Frequency Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Frequency Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Frequency Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Frequency Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Frequency Therapeutics shares will generate the highest return on investment. By understating and applying Frequency Therapeutics stock market price indicators, traders can identify Frequency Therapeutics position entry and exit signals to maximize returns.
Frequency Therapeutics Return and Market Media
The median price of Frequency Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 46.63 with a coefficient of variation of 28.42. The daily time series for the period is distributed with a sample standard deviation of 14.0, arithmetic mean of 49.26, and mean deviation of 11.77. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 08/30/2024 |
2 | Acquisition by Cerio Jeffrey of 40000 shares of Frequency Therapeutics at 44.37 subject to Rule 16b-3 | 09/03/2024 |
3 | 3 Stocks That Could Rise on European Bank Interest Rate Cuts | 09/27/2024 |
4 | Wall Street Analysts Think Korro Bio, Inc. Could Surge 239.54 percent Read This Before Placing a Bet | 10/16/2024 |
5 | Disposition of tradable shares by Agarwal Vineet of Frequency Therapeutics at 82.89 subject to Rule 16b-3 | 10/17/2024 |
6 | Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board | 11/04/2024 |
7 | Disposition of 800 shares by Agarwal Vineet of Frequency Therapeutics at 70.0 subject to Rule 16b-3 | 11/11/2024 |
8 | Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/12/2024 |
9 | Korro Bio Sees Large Volume Increase Following Better-Than-Expected Earnings | 11/13/2024 |
10 | Korro Bio Given Outperform Rating at William Blair | 11/14/2024 |
11 | Korro Bio Earns Buy Rating from HC Wainwright | 11/15/2024 |
12 | Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 12a Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency | 11/21/2024 |
13 | Korro Bio Given Buy Rating at HC Wainwright | 11/22/2024 |
About Frequency Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Frequency or other stocks. Alpha measures the amount that position in Frequency Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 364.33 | 363.24 | Receivables Turnover | 97.9 | 57.9 |
Frequency Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Frequency Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Frequency Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Frequency Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Frequency Therapeutics. Please utilize our Beneish M Score to check the likelihood of Frequency Therapeutics' management manipulating its earnings.
| 8th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Frequency Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Frequency Therapeutics Backtesting, Frequency Therapeutics Valuation, Frequency Therapeutics Correlation, Frequency Therapeutics Hype Analysis, Frequency Therapeutics Volatility, Frequency Therapeutics History and analyze Frequency Therapeutics Performance. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Frequency Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.